Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy.

palliative (6 months PFS and 14 months OS) therapy, however this did not reach statistical significance ( Table 3 and Table S2 ).

also in 111,027 other papers

T-test analysis of mean cell numbers at baseline compared to specimens under IL-2 therapy showed a highly significant increase in CD4 + and CD8 + T cells in the group of responders ( Figure 4 b).

also in 132,142 other papers